LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study

BACKGROUND: Osilodrostat, a potent oral inhibitor of 11β-hydroxylase, demonstrated efficacy in normalizing urinary free cortisol (UFC) in Cushing's disease (CD) patients; however, information describing its use in clinical practice is limited. We present osilodrostat dosing and titration inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioachimescu, Adriana Gabriela, Joseph Auchus, Richard, Huang, Wenyu, Spencer-Segal, Joanna L, Ji Yuen, Kevin Choong, Dacus, Kelley C, Ludlam, William Henry, Babler, Elizabeth Kay, Das, Ashis K, Campos, Cynthia, Broder, Michael S, Fleseriu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626922/
http://dx.doi.org/10.1210/jendso/bvac150.983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626922/
http://dx.doi.org/10.1210/jendso/bvac150.983

Ejemplares similares